GRAIL, Inc. $GRAL Position Trimmed by Cetera Investment Advisers

Cetera Investment Advisers trimmed its position in shares of GRAIL, Inc. (NASDAQ:GRAL) by 5.2% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 16,508 shares of the company’s stock after selling 906 shares during the quarter. Cetera Investment Advisers’ holdings in GRAIL were worth $422,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also made changes to their positions in the company. State of Tennessee Department of Treasury acquired a new stake in shares of GRAIL during the 4th quarter valued at about $28,000. Caldwell Sutter Capital Inc. acquired a new stake in shares of GRAIL during the 1st quarter valued at about $28,000. Sterling Capital Management LLC acquired a new stake in shares of GRAIL during the 4th quarter valued at about $29,000. KBC Group NV lifted its holdings in shares of GRAIL by 187.7% during the 1st quarter. KBC Group NV now owns 1,430 shares of the company’s stock valued at $37,000 after buying an additional 933 shares during the last quarter. Finally, S.A. Mason LLC lifted its holdings in shares of GRAIL by 50.1% during the 1st quarter. S.A. Mason LLC now owns 1,499 shares of the company’s stock valued at $38,000 after buying an additional 500 shares during the last quarter.

GRAIL Stock Performance

GRAL opened at $32.43 on Monday. The business has a 50 day moving average price of $40.12 and a 200 day moving average price of $36.33. GRAIL, Inc. has a twelve month low of $12.33 and a twelve month high of $63.99. The firm has a market cap of $1.17 billion, a P/E ratio of -2.47 and a beta of 3.26.

GRAIL (NASDAQ:GRAL) last posted its earnings results on Tuesday, August 12th. The company reported ($3.18) earnings per share for the quarter, missing the consensus estimate of ($3.14) by ($0.04). GRAIL had a negative return on equity of 16.64% and a negative net margin of 329.86%. The company had revenue of $35.54 million during the quarter, compared to analyst estimates of $37.57 million. As a group, analysts anticipate that GRAIL, Inc. will post -15.15 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, Canaccord Genuity Group lifted their price target on GRAIL from $32.00 to $43.00 and gave the company a “buy” rating in a report on Wednesday, May 14th.

Insiders Place Their Bets

In other GRAIL news, CFO Aaron Freidin sold 8,000 shares of GRAIL stock in a transaction that occurred on Tuesday, July 15th. The stock was sold at an average price of $38.93, for a total value of $311,440.00. Following the transaction, the chief financial officer directly owned 286,020 shares of the company’s stock, valued at $11,134,758.60. The trade was a 2.72% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, President Joshua J. Ofman sold 9,692 shares of GRAIL stock in a transaction that occurred on Monday, June 30th. The stock was sold at an average price of $52.00, for a total value of $503,984.00. Following the completion of the transaction, the president directly owned 492,076 shares in the company, valued at approximately $25,587,952. This represents a 1.93% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 357,492 shares of company stock valued at $17,645,718 in the last three months.

About GRAIL

GRAIL, Inc operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T.